Equity Profile

TNGX

Tango Therapeutics, Inc.

Health CareBiotechnology$3.2B

May13Wed

Post-Earnings Recap

ReportedQ1-2026After Close4:07 PM EDT

Tango Therapeutics Misses on EPS, Stock Up 8.55%

Metric	Actual	Expected	Surprise
EPS	$-0.32	$-0.31	-0.95%
Revenue	$—	$1M	—

management commentary, guidance changes, and full analysis available with Pro.

Tango Therapeutics Misses on EPS, Stock Up 8.55%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.32	$-0.31	-0.95%
Revenue	$—	$1M	—

Management Commentary

Tone: Unknown

No transcript is on record for the earnings call, so the analysis is based solely on the numerical results.

What It Means

Tango Therapeutics reported a wider-than-expected loss per share, which may raise concerns among investors. However, the stock reacted positively, increasing by 8.55%. This rise could be attributed to other factors not reflected in the earnings metrics, such as market sentiment or potential future developments.

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a critical measure of profitability, and investors will be keen to see if Tango can narrow its losses this quarter.

$-0.31

Revenue

Revenue figures will indicate the company's ability to generate sales and support its ongoing research and development efforts.

$1M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. Operating in the health care sector, its innovative approach aims to improve patient outcomes through precision medicine, making it a key player in the ongoing fight against cancer.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q4-2025, Tango reported an EPS of $-0.29, slightly better than the expected $-0.31, which led to a positive stock reaction of 36.28% the following day. However, revenue details were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Tango to report a loss this quarter, with a consensus EPS of $-0.31 and revenue around $1M. The market is looking for signs of improvement in both metrics compared to previous quarters.

Bull Case

If Tango can beat the EPS estimate and show stronger revenue growth, it could signal that its therapies are gaining traction, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses on EPS and revenue, it may raise concerns about its financial health and ability to fund future projects, which could negatively impact the stock.

Key Metrics to Watch

EPS

$-0.31

Earnings per share (EPS) is a critical measure of profitability, and investors will be keen to see if Tango can narrow its losses this quarter.

Revenue

$1M

Revenue figures will indicate the company's ability to generate sales and support its ongoing research and development efforts.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Tango report an EPS better than the consensus estimate of $-0.31?

A beat on EPS could indicate improving operational efficiency and investor confidence, which is critical for a biotech firm.

What revenue figure will Tango report, and how does it compare to the expected $1M?

Revenue performance will be crucial for assessing the company's market traction and financial sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Tango's potential for revenue growth, as recent developments in their pipeline could lead to unexpected sales.

Supporting Evidence

The company has a history of beating EPS estimates, which could indicate stronger operational performance than expected.

The options market is pricing a significant move, suggesting that traders anticipate a surprise in either direction.

Key Risk

If revenue comes in significantly above $1M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Tango can maintain investor confidence amid ongoing losses.

Bull Confirmed If

An EPS of better than $-0.28 and revenue exceeding $1M would confirm a bullish outlook.

Bear Confirmed If

An EPS worse than $-0.38 and revenue below $1M would support a bearish perspective.

Pre-Earnings Positioning

Options Market

Implied Move

±20.32%

Historical Avg

±14.0%

Pricing rich

The options market is pricing in a significant move of over 20%, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±20.3% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

2.8%

30d HV

81.5%

Calls (17K)P/C Ratio: 0.19Puts (100)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$961,500.00

38,460 sh

1 insider

Net

$961,500.00

Net selling

Most Active Insiders· 1 open-market trade

President, R&DCrystal Adam
$961,500.00
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations, history suggests the stock could rise by an average of 0.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted response as investors await clearer guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of 3.08% in similar situations.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results that could impact future revenue.
2Details on partnerships or collaborations that may enhance market reach.
3Management's commentary on cost management and operational efficiency.
4Insights into future product pipeline developments.
5Any guidance on expected revenue growth for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ORIX Corporation

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a critical measure of profitability, and investors will be keen to see if Tango can narrow its losses this quarter.

$-0.31

Revenue

Revenue figures will indicate the company's ability to generate sales and support its ongoing research and development efforts.

$1M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Tango can beat the EPS estimate and show stronger revenue growth, it could signal that its therapies are gaining traction, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses on EPS and revenue, it may raise concerns about its financial health and ability to fund future projects, which could negatively impact the stock.

Key Metrics to Watch

EPS

$-0.31

Earnings per share (EPS) is a critical measure of profitability, and investors will be keen to see if Tango can narrow its losses this quarter.

Revenue

$1M

Revenue figures will indicate the company's ability to generate sales and support its ongoing research and development efforts.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Tango report an EPS better than the consensus estimate of $-0.31?

A beat on EPS could indicate improving operational efficiency and investor confidence, which is critical for a biotech firm.

What revenue figure will Tango report, and how does it compare to the expected $1M?

Revenue performance will be crucial for assessing the company's market traction and financial sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Tango's potential for revenue growth, as recent developments in their pipeline could lead to unexpected sales.

Supporting Evidence

The company has a history of beating EPS estimates, which could indicate stronger operational performance than expected.

The options market is pricing a significant move, suggesting that traders anticipate a surprise in either direction.

Key Risk

If revenue comes in significantly above $1M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Tango can maintain investor confidence amid ongoing losses.

Bull Confirmed If

An EPS of better than $-0.28 and revenue exceeding $1M would confirm a bullish outlook.

Bear Confirmed If

An EPS worse than $-0.38 and revenue below $1M would support a bearish perspective.

Pre-Earnings Positioning

Options Market

Implied Move

±20.32%

Historical Avg

±14.0%

Pricing rich

The options market is pricing in a significant move of over 20%, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±20.3% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

2.8%

30d HV

81.5%

Calls (17K)P/C Ratio: 0.19Puts (100)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$961,500.00

38,460 sh

1 insider

Net

$961,500.00

Net selling

Most Active Insiders· 1 open-market trade

President, R&DCrystal Adam
$961,500.00
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations, history suggests the stock could rise by an average of 0.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted response as investors await clearer guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of 3.08% in similar situations.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results that could impact future revenue.
2Details on partnerships or collaborations that may enhance market reach.
3Management's commentary on cost management and operational efficiency.
4Insights into future product pipeline developments.
5Any guidance on expected revenue growth for the next quarter.